CDKN2A and lung carcinoma: In addition, multiplexing detection of cancer‐associated cfDNA biomarkers, including EGFR, TP53, CDKN2A, and PTEN has enabled a noninvasive and cost‐effective cancer diagnosis method for differentiating lung cancer cases.